Card Tech Minutes 2017.05.31

Attendees

• Nick Gawrit, Heartbase, co-chair
• Chris Melo, Philips, co-chair
• Dan Murphy, Epic
• Antje Schroeder, Siemens Healthineers
• Charles Thomas, University of Washington
• Rebecca Baker, ACC
• Andrea Price, Indiana University
• Miranda Jacobson, Philips
• Nakano Shinichi, Canon (Toshiba) and IHE-Japan
• Takeshi Oozeki, Canon (Toshiba) and IHE-Japan
• Wakita, Toshiba and IHE-Japan

Minutes

Update

IVI Profile: IHE Japan

• Proposal for profile from device vendors to RIS vendors to allow wider adoption. IVI is optional part of CATH procedure.

• Presented review of findings after discussions with Dr. Charles Thomas at University of Washington Medicine and Kevin O'Donnell, an expert in scheduled workflow in IHE.

• Presented three options for approach:

• (1) Add "minimal modality" actor to the CATH which does not have MPPS and Commit requirements

• (2) Make IVI Profile which borrows most transactions from CATH but makes optionalities

• (3) Revise the CATH profile to mke the baseline MPPS and Commit optional in the baseline and have Named Options that make them required and make those options mandatory for the CATH profile. (Options should add requirements, not subtract requirements)

• Discussion of all three options throughout the time period. Pros and cons to each option.

• IHE Japan propose for next F2F meeting--have 3 engineers from Terumo who are members of DICOM committees (WG-01) come to Heart house, 1 from Japan and 2 from US. Have engineer from Goodman healthcare come to Heart house from Japan.

• Suggested post to the listserv the proposal and ask for comments and for vendors to attend F2F to join discussion.
• Would like Boston Scientific, St. Jude and Infraredx to join F2F meeting in June too for this discussion.
• Suggested could start on the work now and further develop the plan for F2F in June.
• Would like volunteers to do further analysis, discuss advantages/disadvantages of each approach. Will need "usecases" from the vendor perspective.
• Discussion around the storage of the IVUS/OCT and Angio. Same study different modality, part of the same procedure. IVUS and OCT do not occur without angiography.
• More complex than initially thought. How would these images be viewed later? Will need to know how to capture the procedures from the vendor point of view.
• Suggest document the scheduled workflow in diagram.
• Add hemo waveforms, Hemodyne modality is similar to the other modalities and these have been integrated into the CATH workflow.

• Suggest for F2F- will need 3 hours for IVI presentation, will break it up into two or three one hour or one and half hour sessions. The IVI vendors could do breakout sessions in between times and then bring back thoughts for group discussion.

• May skip next few weeks unless topics brought forward for discussion.

Action Items

• IHE Japan send proposal and questions to listserve
• Paul Dow check with ACC on usage and needs for correlation of IVUS and angio. What is the current process?